 4D pharma PLC AIM:DDD, NASDAQ:LBPS has some significant milestones upcoming this year after a successful 12 months of developing assets that target the human microbiome, the bacterial ecosystem in the gut. The update was provided alongside prelims which showed the drug developer posted a 26.1mln operating loss in the year to 31 December 2021 after it spent 19.8mln on research and development. 